NASDAQ:INDV Indivior Q3 2026 Earnings Results & Report $28.21 +0.06 (+0.21%) As of 11/4/2026 Indivior beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 29, 2026. The company reported EPS of $1.32 versus the $1.06 consensus estimate, while revenue of $356 million topped the $329.35 million estimate by $26.65 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 29, 2026TimeBefore Market OpensConference Call9:00 AM ET Indivior EPS ResultsActual EPS$1.32Consensus EPS $1.06Beat/MissBeat by +$0.26One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersIndivior Revenue ResultsActual Revenue$356 millionExpected Revenue$329.35 millionBeat/MissBeat by +$26.65 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Indivior Q3 2026 Earnings FAQ Did Indivior beat earnings estimates for Q3 2026? Indivior (NASDAQ:INDV) reported earnings of $1.32 per share for Q3 2026, beating the consensus estimate of $1.06. The report was announced on Thursday, October 29, 2026. What was Indivior's revenue for Q3 2026? Indivior reported revenue of $356 million for Q3 2026, against a consensus estimate of $329.35 million. Indivior Earnings HeadlinesIndivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third QuarterOctober 30, 2026 | uk.finance.yahoo.com(INDV) Indivior Expects 2026 Net Revenue Range $1.30B to $1.37B, vs. FactSet Est of $1.33BOctober 29, 2026 | marketscreener.comM$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 21 at 1:00 AM | Profits Run (Ad)Indivior Reports Third Quarter 2026 Financial ResultsOctober 29, 2026 | globenewswire.comIndivior to Report Third Quarter 2026 Financial ResultsOctober 19, 2026 | globenewswire.comIndivior: Sublocade Growth And Improving Profitability Create Upside PotentialOctober 14, 2026 | seekingalpha.comSee More Indivior Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indivior? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indivior and other key companies, straight to your email. Email Address About IndiviorIndivior (NASDAQ:INDV) is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs. Indivior was formed in 2014 when Reckitt Benckiser separated its pharmaceutical business. It serves patients and healthcare providers in the United States and other markets, with a substantial focus on the U.S. addiction-treatment market.View Indivior ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.